-+ 0.00%
-+ 0.00%
-+ 0.00%

BioPorto 9M adjusted EBITDA loss narrows 19% to DKK 51.5 million

PUBT·11/19/2026 06:54:50
Listen to the news
BioPorto 9M adjusted EBITDA loss narrows 19% to DKK 51.5 million
  • BioPorto reported a third-quarter 2026 adjusted EBITDA loss of DKK 16.8 million.
  • The U.S. adult validation study entered active execution, with study sites activated and the first patients enrolled during the quarter.
  • Five U.S. university hospitals became NGAL research-use customers, bringing the total to 59 at quarter-end.
  • Full-year 2026 guidance remained unchanged, including an adjusted EBITDA loss of DKK 58 million–DKK 68 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioPorto A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611190153OMX_____CNEWS_DA_GNW1001304423_da) on November 19, 2026, and is solely responsible for the information contained therein.